Loading company…
Radiant Biotherapeutics develops multivalent and multispecific antibody medicines for cancer, autoimmune and infectious diseases.
Founded in 2020 and based in Toronto, Canada, Radiant Biotherapeutics develops antibody-based therapies using its multabody platform. Its research targets cancer, autoimmune and infectious diseases. In September 2024, the company raised CAD 35 million in series A funding co-led by Bill & Melinda Gates Foundation Trust and Amplitude, with participation from BDC Capital, Abrdn, Fight Against Cancer Innovation Trust, Alexandria Angel Network and TIAP.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in